3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Conventionally, optimal treatment strategies for breast cancer have been largely determined by physicians, with a scant understanding of patients’ treatment values and preferences. Incorporating patient preferences in the decision-making process for breast cancer treatment is gaining recognition and can potentially improve treatment outcomes and compliance. This scoping review aims to synthesize evidence on the key determinants that are most valued by breast cancer patients when deciding on their treatment options.

          Methods

          We searched three electronic databases (PubMed/MEDLINE, SCOPUS, and CINAHL Plus) utilizing a systematic scoping review method. Two reviewers independently screened, applied inclusion criteria, reviewed, and synthesized findings. A mixed-method narrative approach combining the inductive thematic analysis and content analysis methodologies was used to synthesize and summarize the findings.

          Results

          The review included 22 studies, leading to the conceptualization of 5 overarching themes and 17 sub-themes. Among these, the most frequently cited theme was treatment benefits, followed by treatment-related process, treatment-related risk, quality of life, and cost of treatment. Women with breast cancer highly value treatments that offer good effectiveness, prolong survival, prevent recurrence, and maintain quality of life. Patient concerns include treatment-related side effects, safety, the risk of secondary cancer, and direct or indirect out-of-pocket costs. Additionally, patients also consider treatment duration, mode of administration, physician recommendation, and treatment availability and accessibility when deciding on their preferred treatment.

          Conclusion

          The evidence synthesized in this review offers insights into refining breast cancer treatment strategies to align more closely with patient values. Recognizing and integrating patient perspectives in breast cancer care could potentially lead to improved treatment outcomes, enhanced patient compliance, and more personalized care. Healthcare professionals are encouraged to incorporate these key determinants in their treatment decision-making processes, aiming to deliver a patient-centered care that aligns with the unique preferences and values of each patient.

          Plain Language Summary

          Breast cancer is a significant health concern, and treatment decisions have traditionally driven by physicians, often without due consideration for patients’ preferences in their treatment choices. This scoping review aimed to explore and summarize what matters most to breast cancer patients when deciding on their treatment options. We found five main themes that were important to patients:

          1. Effectiveness: Patients highly value treatments that are effective in fighting cancer, prolonging survival, and preventing recurrence.

          2. Treatment-related process: The length of treatment and availability of different therapies influenced patients’ choices. Patients trust their doctors’ expertise but also value being involved in the decision-making process to have their preferences considered.

          3. Side Effects and Safety: Concerns about treatment-related side effects and the risk of secondary cancer were critical factors in decision-making.

          4. Quality of Life: Maintaining a good quality of life during treatment is crucial for patients.

          5. Financial Burden: The additional direct and indirect out-of-pocket costs of treatment were important considerations for patients.

          Understanding patients’ preferences is vital in developing personalized treatments that align with their values. Healthcare professionals need to communicate effectively with patients and involve them in the decision-making process. Patient decision aids and tailored financial assistance programs could also be helpful. Further research is needed to identify effective strategies to tailor treatments to meet patients’ preferences. Overall, this review sheds light on what matters most to breast cancer patients, empowering them to be more active participants in their treatment decisions and potentially improving treatment outcomes and overall well-being.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Scoping studies: towards a methodological framework

                Bookmark

                Author and article information

                Journal
                Patient Prefer Adherence
                Patient Prefer Adherence
                ppa
                Patient preference and adherence
                Dove
                1177-889X
                31 October 2023
                2023
                : 17
                : 2679-2706
                Affiliations
                [1 ]School of Pharmacy, University of Otago , Dunedin, New Zealand
                [2 ]Clinical Research Center, Hospital Seberang Jaya , Penang, Malaysia
                [3 ]Faculty of Medical and Health Sciences, University of Auckland , Auckland, New Zealand
                Author notes
                Correspondence: Carlo A Marra, School of Pharmacy, University of Otago , PO Box 56, Dunedin, 9054, New Zealand, Tel +64-34797275, Fax +64-34797034, Email carlo.marra@otago.ac.nz
                Author information
                http://orcid.org/0000-0002-9690-3532
                http://orcid.org/0000-0003-4714-6130
                http://orcid.org/0000-0003-1016-3113
                http://orcid.org/0000-0002-2625-2121
                Article
                432821
                10.2147/PPA.S432821
                10625390
                37927344
                02feb737-fec2-405a-bbba-9720ea1bb909
                © 2023 Yeo et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 03 August 2023
                : 07 October 2023
                Page count
                Figures: 1, Tables: 3, References: 63, Pages: 28
                Funding
                Funded by: Health Research Council of New Zealand Health Delivery Research Activation grant;
                This work was supported by the Health Research Council of New Zealand Health Delivery Research Activation grant.
                Categories
                Review

                Medicine
                breast cancer,patient preference,treatment decision making,narrative scoping review
                Medicine
                breast cancer, patient preference, treatment decision making, narrative scoping review

                Comments

                Comment on this article